Start from a saved view, or filter by area, exchange and headquarters. Each row shows the pipeline, its most advanced asset and the next readout on record.
Lists by late-stage drug kind: biologics, small molecules, cell and gene therapies, RNA and oligonucleotide drugs, peptide drugs.
1457 of 1457 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Usynova Pharmaceuticals Ltd.Private | 1 asset: 1 Ph 1 | UA026Phase 1 · Psoriasis | None on record | — | — | — | — |
Uvax BioPrivate | 1 asset: 1 Ph 1 | UVAX-1107Phase 1 · HIV | None on record | — | — | — | — |
Valo Therapeutics OyPrivate | 1 asset: 1 Ph 1 | PeptiCRAd-1Phase 1 · Non-Small Cell Lung Cancer | 30 Apr 2027PeptiCRAd-1 · Phase 1 | — | — | — | — |
Valorum Biologics LLCPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Vantive HealthPrivate | 1 asset: 1 Ph 3 | Icodextrin (peritoneal ultrafiltration)Phase 3 · Heart FailureWeak signal | None on record | — | — | — | — |
Vasa TherapeuticsPrivate | 1 asset: 1 Ph 1 | Vasa Therapeutics VS-041Phase 1 · Heart Failure | Nov 2026Vasa Therapeutics VS-041 · Phase 1 | — | — | — | — |
Vascarta Inc.Private | 1 asset: 1 Ph 1 | VAS-101Phase 1 · Sickle Cell Disease | None on record | — | — | — | — |
Vaxine Pty LtdPrivate | 1 asset: 1 Ph 2 | HepadvaxPhase 1/2 · Chronic Hepatitis B | 1 Mar 2027Hepadvax · Phase 1/2 | — | — | — | — |
VentrixPrivate | 1 asset: 1 Ph 1 | VentriGelPhase 1 · Heart FailureWeak signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | VENT-03Phase 2 · Systemic Lupus Erythematosus | Dec 2026VENT-03 · Phase 2 | — | — | — | — | |
Verdiva BioPrivate | 1 asset: 1 Ph 2 | Ecnoglutide (VRB-101)Phase 2 · ObesityPartial signal | 5 Jan 2027Ecnoglutide (VRB-101) · Phase 1/2 | — | — | — | — |
Verity PharmaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
VERO BiotechPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Vertero TherapeuticsPrivate | 1 asset: 1 Ph 1 | VT-5006Phase 1 · Parkinson's Disease | None on record | — | — | — | — |
Verve TherapeuticsPrivate | 2 assets: 1 Ph 2, 1 Ph 1 | VERVE-102Phase 2 · Atherosclerotic Cardiovascular Disease | Dec 2027VERVE-201 · Phase 1 | — | $502MMar 2025 | ~16.2 qtrs | $210M |
| 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — | |
Vifor PharmaPrivate | 7 assets: 5 approved, 1 Ph 3, 1 Ph 2 | PatiromerPhase 3 · Chronic Kidney DiseasePartial signal | Mar 2027sparsentan · Approved | — | — | — | — |
ViiV HealthcarePrivate | 10 assets: 5 approved, 4 Ph 2, 1 Ph 1 | DezecapavirPhase 2 · HIVPartial signal | 22 Jan 2027Fostemsavir · Phase 1 | — | — | — | — |
Vimgreen PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | VG081821ACPhase 2/3 · Parkinson's Disease | 1 Oct 2027VG081821AC · Phase 2/3 | — | — | — | — |
Vincentage PharmaPrivate | 1 asset: 1 Ph 3 | VCT220Phase 3 · ObesityReliable signal | 1 Jul 2027VCT220 · Phase 2 | — | — | — | — |
ViriomPrivate | 1 asset: 1 Ph 3 | ElsulfavirinePhase 2/3 · HIVPartial signal | None on record | — | — | — | — |
Virogenics, Inc.Private | 1 asset: 1 Ph 1 | CMS121Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Vitrac Therapeutics, LLCPrivate | 1 asset: 1 Ph 1 | VIC-1911Phase 1 · Non-Small Cell Lung CancerWeak signal | None on record | — | — | — | — |
Vivace Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | VT3989Phase 1/2 · Non-Small Cell Lung Cancer | 1 May 2028VT3989 · Phase 3 | — | — | — | — |
| 1 asset: 1 Ph 2 | EtribnabdionePhase 2 · Atherosclerotic Cardiovascular Disease | Mar 2027Etribnabdione · Phase 2 | — | — | — | — | |
VIVUSPrivate | 2 assets: 1 approved, 1 Ph 3 | Extended-release tacrolimus (VI-0106)Phase 3 · Pulmonary Arterial Hypertension | 31 May 2028Extended-release tacrolimus (VI-0106) · Phase 3 | — | — | — | — |
VM Discovery, Inc.Private | 1 asset: 1 Ph 2 | VMD-102Phase 1/2 · Non-Small Cell Lung Cancer | May 2031VMD-102 · Phase 1/2 | — | — | — | — |
VM Oncology, LLCPrivate | 1 asset: 1 Ph 2 | VMD-928Phase 1/2 · Non-Small Cell Lung Cancer | Dec 2027VMD-928 · Phase 1/2 | — | — | — | — |
Volastra Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | OrvanesibPhase 1/2 · Non-Small Cell Lung Cancer | None on record | — | — | — | — |
VRisePrivate | 1 asset: 1 Ph 2 | KQ-2003Phase 1/2 · Multiple MyelomaWeak signal | 31 Dec 2027KQ-2003 · Phase 1 | — | — | — | — |
VTBIO Co. Ltd (South Korea)Private | 1 asset: 1 Ph 1 | VT301Phase 1 · Alzheimer's DiseaseWeak signal | None on record | — | — | — | — |
Vyriad, Inc.Private | 1 asset: 1 Ph 2 | VSV-IFNβ-NISPhase 2 · Melanoma | None on record | — | — | — | — |
Waylis Therapeutics LLCPrivate | 4 assets: 4 approved | Approved assets only | None on record | — | — | — | — |
Welichem BiotechPrivate | 1 asset: 1 approved | Approved assets only | Aug 2027Tapinarof · Phase 3 | — | — | — | — |
Windward BioPrivate | 1 asset: 1 Ph 3 | WIN378Phase 2/3 · AsthmaWeak signal | 17 Dec 2027WIN378 · Phase 2 | — | — | — | — |
WinHealth PharmaPrivate | 1 asset: 1 approved | Approved assets only | 15 Aug 2029Difelikefalin · Phase 2 | — | — | — | — |
WinSanTorPrivate | 1 asset: 1 Ph 2 | Pirenzepine (topical)Phase 2 · Diabetic Peripheral Neuropathic PainPartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 1 | UWD-00BPhase 1 · Multiple Myeloma | None on record | — | — | — | — | |
| 1 asset: 1 Ph 3 | QR12000Phase 3 · HypertensionPartial signal | None on record | — | — | — | — | |
Xantho BiotechnologyPrivate | 1 asset: 1 Ph 2 | GM-XANTHOPhase 2 · PsoriasisPartial signal | 31 Dec 2027GM-XANTHO · Phase 2 | — | — | — | — |
Xcovery HoldingsPrivate | 1 asset: 1 approved | Approved assets only | 1 Feb 2029Ensartinib · Phase 1/2 | — | — | — | — |
| 1 asset: 1 Ph 2 | XS-411Phase 1/2 · Parkinson's Disease | 30 Mar 2028XS-411 · Phase 1/2 | — | — | — | — | |
| 1 asset: 1 other | Yangxin Dawayimixike Honey PasteAtherosclerotic Cardiovascular Disease | Jul 2028Yangxin Dawayimixike Honey Paste · Approved | — | — | — | — | |
XYone Therapeutics, IncPrivate | 1 asset: 1 Ph 2 | XYA02Phase 1/2 · Non-Small Cell Lung Cancer | 15 Sep 2029XYA02 · Phase 1/2 | — | — | — | — |
Yabao Pharmaceutical GroupPrivate | 1 asset: 1 Ph 2 | Globalagliatin HydrochloridePhase 2 · Type 2 DiabetesPartial signal | None on record | — | — | — | — |
| 1 asset: 1 Ph 2 | VB19055Phase 2 · Hypertension | Dec 2027VB19055 · Phase 2 | — | — | — | — | |
Yaso TherapeuticsPrivate | 1 asset: 1 other | YASO GELHIV | Feb 2028YASO GEL · Phase 1 | — | — | — | — |
Zambon SpAPrivate | 3 assets: 2 approved, 1 Ph 1 | Voriconazole (ZP-059)Phase 1 · AsthmaWeak signal | None on record | — | — | — | — |
Zensun (Shanghai) Sci & TechPrivate | 1 asset: 1 Ph 3 | Recombinant human neuregulin-1 (rhNRG-1)Phase 3 · Heart FailurePartial signal | None on record | — | — | — | — |
Zenyaku KogyoPrivate | 1 asset: 1 approved | Approved assets only | 1 Dec 2026Rituximab · Phase 2 | — | — | — | — |
| 1 asset: 1 Ph 1 | CBG002Phase 1 · Multiple Myeloma | 25 Oct 2027CBG002 · Phase 1 | — | — | — | — | |
Zhejiang Doer BiologicsPrivate | 1 asset: 1 Ph 3 | DR10624Phase 3 · Severe HypertriglyceridemiaPartial signal | Apr 2028DR10624 · Phase 2 | — | $15.7BJun 2026 | ~18.0 qtrs | ~$2.4B |
| 1 asset: 1 Ph 2 | XKH001Phase 2 · Atopic Dermatitis | 1 Apr 2027XKH001 · Phase 1 | — | — | — | — | |
| 1 asset: 1 Ph 2 | PA1010Phase 1/2 · Chronic Hepatitis B | None on record | — | — | — | — | |
Zhimeng BiopharmaPrivate | 2 assets: 1 Ph 3, 1 Ph 1 | CB03-154Phase 2/3 · Amyotrophic Lateral Sclerosis | Sep 2027CB03-154 · Phase 2 | — | — | — | — |
Zhiyi PharmaceuticsPrivate | 1 asset: 1 Ph 2 | Live SK08Phase 2 · Ulcerative Colitis | None on record | — | — | — | — |
Zumutor Biologics Inc.Private | 1 asset: 1 Ph 1 | ZM008Phase 1 · Non-Small Cell Lung Cancer | Dec 2026ZM008 · Phase 1 | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.